Key Details
Price
$2.26Annual ROE
161.93%Beta
2.35Events Calendar
Next earnings date:
Mar 13, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Start Time: 08:30 January 1, 0000 9:04 AM ET ADC Therapeutics SA (NYSE:ADCT ) Q2 2024 Earnings Conference Call August 06, 2024, 08:30 AM ET Company Participants Ameet Mallik - CEO Jose Carmona - CFO Marcy Graham - IRO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Michael Schmidt - Guggenheim Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Didi, and I will be your operator for today's call.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.58 per share a year ago.
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.
ADC Therapeutics SA (NYSE: ADCT) has revealed that Ameet Mallik, the Chief Executive Officer, will be taking part in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 2:00 p.m. ET.
ADC Therapeutics SA (ADCT) reported a quarterly loss of $0.56 per share, which was in line with the Zacks Consensus Estimate. This is an improvement from the loss of $0.74 per share reported in the same quarter last year.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FAQ
- What is the primary business of ADC Therapeutics SA?
- What is the ticker symbol for ADC Therapeutics SA?
- Does ADC Therapeutics SA pay dividends?
- What sector is ADC Therapeutics SA in?
- What industry is ADC Therapeutics SA in?
- What country is ADC Therapeutics SA based in?
- When did ADC Therapeutics SA go public?
- Is ADC Therapeutics SA in the S&P 500?
- Is ADC Therapeutics SA in the NASDAQ 100?
- Is ADC Therapeutics SA in the Dow Jones?
- When was ADC Therapeutics SA's last earnings report?
- When does ADC Therapeutics SA report earnings?
- Should I buy ADC Therapeutics SA stock now?